


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 – 24 (Cancelled)

25. (Previously presented) A compound of the general formula (I):




wherein


ring A is phenyl;

R^A is selected from: -(CH₂)_pCN, -C(=NR¹)-SMe and -C(=NR¹)-OMe , or


R^A is selected from one of the following groups of formula (2), formula (3) and formula (4):



(2)



(3)



(4)

wherein p is 0, 1 or 2;

s is 1;

R¹ and R² are independently selected from: H, hydroxy, alkyl, partially or fully fluorinated alkyl, alkoxy, alkenyl, alkynyl, carboxy, -C(=O)OR⁵, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl and heterocycle; or R¹ and R², together with the nitrogen atom to which they are attached, form a saturated, partially saturated or aromatic heterocycle, optionally containing at least one additional hetero atom selected from: N, O and S;

R³ and R⁴ are independently selected from: H, alkyl, partially or fully fluorinated alkyl, alkenyl, alkynyl, -C(=O)OR⁵, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycle, -OR⁵, -SR⁵, -NR⁵R⁶, -S(=O)₂NR⁵R⁶, -S(=O)₂R⁵, -C(=O)R⁵, -C(=O)NR⁵R⁶, -C(=O)OR⁵, -C(=O)SR⁵, -OC(=O)R⁵, -OC(=O)OR⁵, -OC(=O)NR⁵R⁶, -OS(=O)₂R⁵, -S(C=O)NR⁵ and -OS(=O)₂NR⁵R⁶, or R³ and R¹ or R⁴, together with the respective nitrogen atoms to which they are attached, form an unsubstituted or substituted 5-, 6- or 7-membered partially saturated or aromatic heterocycle, optionally having one or more additional heteroatoms selected from: N, O and S, wherein the substituents are selected from: hydroxy, halogen, alkyl, alkoxy, alkenyl, alkynyl, oxo, carboxy and -C(=O)OR⁵,

R⁵ and R⁶ are independently selected from: H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl and heterocycle, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkylalkyl group optionally contains at least one hetero atom selected from: N, S and O anywhere in the chain, including the terminal position;

R⁷ and R⁹ have the same meaning as R³ and R⁴, defined above;

R⁸ is selected from: H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl and heterocycle, wherein said heterocycle is saturated, partially saturated or aromatic and contains at least one hetero atom selected from: N, O and S, with its point of attachment either through C or N, and wherein each of

said alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkylalkyl groups optionally contains at least one hetero atom selected from: N, O and S, anywhere in the chain, including the terminal position;

R^B is selected from: H, halogen, -CN, -NO₂, alkyl, partially or fully fluorinated alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycle, -NR¹⁰R¹¹, -OR¹⁰, -SR¹⁰, S(O)R¹⁰, S(O)₂R¹⁰, -NHC(=O)R¹⁰, -NHOR¹⁰, -OC(=O)R¹⁰, -SC(=O)R¹⁰, -NHC(=O)OR¹⁰, -OC(=O)OR¹⁰, -C(=O)NR¹⁰R¹¹, -C(=O)R¹⁰, and -C(=O)OR¹⁰;

R¹⁰ and R¹¹ have the same meaning as R⁵ and R⁶, defined above

Y¹ and Y², together, are selected from: =O and =S;

R¹² and R¹³ are selected from: H, OR⁵, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl and aryl;

Z is N;

W is CH₂;

R^C is selected from: H, alkyl, aryl, heterocycle, =O, =NR¹⁴, =S, CN, NR¹⁴R¹⁵, OR¹⁴, SR¹⁴, S(=O)₂R¹⁶ and COR¹⁶;

R¹⁴ and R¹⁵ have the same meaning as R⁵ and R⁶, defined above;

R¹⁶ is selected from: H, OR¹⁴, N(R¹⁴)₂, NR¹⁴R¹⁵, SR¹⁴ and R⁵, wherein R⁵, R¹⁴ and R¹⁵ are as defined above;

n is 0, 1, 2 or 3;

R^D and R^E are independently selected from: H and an unsubstituted or substituted group selected from: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl and heterocycle, wherein the substituents are selected from: hydroxy, halogen, alkyl, alkenyl, alkynyl, oxo, carboxy, -C(=O)OR⁵, -OR¹⁷, -SR¹⁷, -NR¹⁷R¹⁸, -NHC(=O)R¹⁷, -NHC(=O)OR¹⁷, -OC(=O)R¹⁷, -SC(=O)R¹⁷, -OS(=O)₂R¹⁷ and -NHS(=O)₂R¹⁷;

R¹⁷ and R¹⁸ have the same meaning as R⁵ and R⁶, defined above;

R^F is selected from: O, S and N(OR¹⁹);

R¹⁹ and R²⁰ have the same meaning as R⁵ and R⁶, defined above;

R^G is selected from: aryl, heteroaryl, and partially or fully saturated heterocycle, where said aryl, heteroaryl and heterocycle are substituted by one or more groups of the formula (5):



and optionally, further substituted by one or more groups selected from: -R⁵, halogen, -CN, -SCN, -CNO, -OR²¹, -OC(=O)R²¹, -OS(=O)₂R²¹, -OS(=O)₂NR²¹R²², -OC(=O)OR²¹, -OC(=O)SR²¹, -OC(=O)NR²¹R²², -SR²¹, -S(=O)R²¹, -NO₂, -NR²¹(OR²²), -NR²¹R²², -NR²¹C(=O)R²², -N(R²¹)C(=O)OR²², -N[S(=O)₂R²¹]R²³, C(=O)OR²¹, -S(=O)₂R²¹ and -S(=O)₂OR²¹;

R²¹ and R²² have the same meaning as R¹ and R², defined above:

T is selected from: -CH₂, O, S and NH;

q is 0, 1, 2 or 3;

R²³ and R²⁴ are independently selected from: H, alkyl alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycle and C(=O)R²⁵, wherein said alkyl and alkenyl optionally contain at least one hetero atom selected from: O, S and N, in any position of the alkyl or alkenyl chain, and said alkyl and alkenyl are unsubstituted or substituted with at least one group selected from: -OR¹, -OC(=O)R¹, -OS(=O)₂R¹, -S(=O)₂NR¹R², -OC(=O)OR¹, -OC(=O)SR¹, -OC(=O)NR¹R², -SR¹, -S(=O)R¹, -SC(=O)H, -SC(=O)OR¹, -NR¹(OR²), -NR¹R², -NR¹C(=O)R², -N(R¹)C(=O)OR², -NR¹S(=O)₂R², C(=O)OR¹, -S(=O)₂R¹ and -S(=O)₂OR¹;

R²⁵ is selected from: OR⁵, SR⁵, -OCR³R⁴ and -NR⁵R⁶, wherein R³, R⁴, R⁵ and R⁶ are as defined above and wherein optionally, R³ and R⁴, together with the carbon

to which they are attached, form an unsubstituted or substituted 5-, 6- or 7-membered saturated, partially saturated or aromatic heterocycle having one or more heteroatoms selected from: N, O and S, wherein the substituents are selected from: hydroxy, halogen, alkyl, alkoxy, alkenyl, alkynyl, oxo, carboxy and -C(=O)OR⁵; and the group NR⁶R⁶ is, optionally, a heterocycle containing at least one additional heteroatom selected from: O, S, and N; in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and its pharmaceutically acceptable salts and pharmaceutically acceptable solvates.

26. (Previously presented) A compound according to claim 1, wherein R^G is selected from: phenyl, piperidinyl and piperazinyl.
27. (Previously presented) A compound according to claim 1, wherein R^A is a group of the formula (3);
R₁ is hydrogen;
R₃ and R₄ are independently selected from: H, OH, -C(O)OH and -C(O)Oalkyl;
R^B = R^C = R^D = R^E = hydrogen;
Y¹ and Y², together are =O;
n is the integer 0 or 1;
R^G is phenyl, substituted with one or more of the group -T-(CH₂)_q-CH₂-C(O)R²⁵ and, optionally, further substituted with one or more of the groups selected from: hydroxy, halogen, alkyl, alkoxy, alkenyl, alkynyl, oxo, carboxy, -C(=O)OR⁵, SR²¹, S(=O)₂R²¹ and -N(R²¹)₂C(O)CH₃, -CH₂C(O)R²⁵;
R²⁵ is selected from: OR⁵, OCR³R⁴ and NR⁵R⁶, wherein R³ and R⁴, together with the carbon to which they are attached form an unsubstituted or substituted 5-, 6- or 7- membered saturated, partially saturated or aromatic heterocycle having

one or more heteroatoms selected from: N, O and S, wherein the substituents are selected from: hydroxy, halogen, alkyl, alkoxy, alkenyl, alkynyl, oxo, carboxy, -C(=O)OR⁵; and

R⁵, R⁶ and R²¹ are independently selected from: H, alkyl and phenyl.

28. (Previously presented) A compound according to claim 1, wherein
R^A is a group of the formula (3);
R₁ is hydrogen;
R₃ and R₄ are independently selected from: H, OH, -C(O)OH and -C(O)Oalkyl;
R^B = R^C = R^D = R^E = hydrogen;
Y¹ and Y², together are =O;
n is the integer 0 or 1;
R^G is selected from: piperidinyl and piperazinyl, wherein said piperidinyl and piperazinyl are substituted with one or more of the group -T-(CH₂)_q-CH₂-C(O)R²⁵ and, optionally, further substituted with one or more groups selected from: hydroxy, halogen, alkyl, alkoxy, alkenyl, alkynyl, oxo, carboxy and -C(=O)OR⁵;
and
R²⁵ is OR⁵, wherein R⁵ is selected from: H, alkyl and phenyl.

29. (Previously presented) A compound according to claim 1 selected from:
(4- {2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid methyl ester;
(4-{2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid methyl ester;
(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid ethyl ester;
(4-{2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-

phenoxy)-acetic acid ethyl ester;

4-(2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl)-phenoxy)-acetic acid isopropyl ester;

(4-{2-[5-(Imino-methoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isopropyl ester;

(4-{2-[5-(Imino-isobutoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isopropyl ester;

(4-{2-[5-(Benzylloxycarbonylamino-imino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isopropyl ester;

(4-{2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isopropyl ester;

(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-(Imino-methoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-(Imino-isobutoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-(Benzylloxycarbonylamino-imino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-(Imino-methanesulfonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid benzyl ester;

(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid;

(4-{2-[5-(Imino-methoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid benzyl ester;

(4-{2-[5-(Imino-isobutoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid benzyl ester;

(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-ethoxy carbonyl methoxy-phenoxy)-acetic acid ethyl ester;

(2-Ethoxycarbonylmethoxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid ethyl ester;

(2-Ethoxycarbonylmethoxy-4-{2-[5-(imino-{3-methyl-butryrylamino}-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid ethyl ester;

(2-Ethoxycarbonylmethoxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-1-hydroxyimino-ethyl}-phenoxy)-acetic acid ethyl ester;

(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-isobutoxy carbonyl methoxy-phenoxy)-acetic acid isobutyl ester;

2-(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-NN-diethyl-acetamide;

4-(2-{4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl)-acetyl]-phenoxy})-acetoxy-piperidine-1-carboxylic acid benzyl ester;

4-Benzylloxycarbonylamino-2-(4-{2-[5-carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-butyric acid ethyl ester;

4-Benzylloxycarbonylamino-2-(4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-butyric acid ethyl ester;

(4-{2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenylsulfanyl)-acetic acid methyl ester;

Applicant: Bansilal et al.
Application No.: 10/574,982

(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-2-chloro-phenoxy)-acetic acid ethyl ester;

(2-Chloro-4-[2-[5-(imino-isobutoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2-Chloro-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-2-ethyl sulfanyl-phenoxy)-acetic acid ethyl ester;

(2-Ethylsulfanyl-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-2-ethane sulfonyl-phenoxy)-acetic acid ethyl ester;

(2-Ethanesulfonyl-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2,6-Bis-ethylsulfanyl-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2-Acetylamino-4-[2-[5-N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2-(Ethoxycarbonylmethyl-methanesulfonyl-amino)-4-[2-[5-(imino-isobutoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2-(Ethoxycarbonylmethyl-methanesulfonyl-amino)-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-hydroxy-phenoxy)-acetic acid ethyl ester;

(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid benzyl ester;

(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-hydroxy-phenoxy)-acetic acid;

(4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-methoxy-phenoxy)-acetic acid ethyl ester;

(4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-propoxy-phenoxy)-acetic acid ethyl ester;

(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-ethoxy carbonylmethoxy-phenoxy)-acetic acid ethyl ester;

(3-Ethoxycarbonylmethoxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid;

(2-Ethylsulfanyl-3-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2-Ethyl-5-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(5-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-2-isopropyl-phenoxy)-acetic acid ethyl ester;

(2-*tert*-Butyl-5-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2-Chloro-5-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2-Chloro-3-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-2-methyl-phenoxy)-acetic acid ethyl ester;

(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-2-methyl-phenoxy)-acetic acid benzyl ester;

(2-Ethyl-3-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-2-propyl-phenoxy)-acetic acid ethyl ester;

(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-2-propyl-phenoxy)-acetic acid benzyl ester;

(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-hydroxy-2-propyl-phenoxy)-acetic acid;

(4-Hydroxy-3-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-5-methoxy-phenoxy)-acetic acid ethyl ester;

(3,5-Dihydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2-Ethoxycarbonylmethoxy-3-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-aceic acid ethyl ester;

(2-Ethoxycarbonylmethoxy-5-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-piperazine-1-yl)-acetic acid ethyl ester;

(1-[2S-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-3-(4-hydroxy-phenyl)-propionyl]-piperidin-4-yloxy)-acetic acid ethyl ester;

(1-{2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-piperidin-4-yloxy)-acetic acid ethyl ester;

(1-{3-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionyl}-piperidin-4-yloxy)-acetic acid ethyl ester;

(1-{2-[5-(5-Methyl-isoxazol-3-yl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-piperidin-4-yloxy)-acetic acid ethyl ester;

(1-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-piperidin-4-yloxy)-acetic acid ethyl ester;

(1-{2-[5-(*tert*-Butoxycarbonylamino-imino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-piperidin-4-yloxy)-acetic acid ethyl ester;

(1-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-piperidin-4-yloxy)-acetic acid;

(4-{2-[5-Acetimidoylamino-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-3-hydroxy-phenoxy)-acetic acid ethyl ester;

(3-Ethoxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid ethyl ester;

(4-{2-[5-carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-3-ethoxy-phenoxy)-acetic acid ethyl ester;

(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-3-ethoxy-phenoxy)-acetic acid;

(3-Hydroxy-4-{2-[1-oxo-5-(5-oxo-2,5-dihydro-[1,2,4]oxadiazol-3-yl)-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid ethyl ester;

(4-{2-[5-(Acetylamino-imino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-3-hydroxy-phenoxy)-acetic acid ethyl ester;

(3-Acetoxy-4-{2-[5-(5-methyl-[1,2,4]oxadiazol-3-yl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid ethyl ester;

(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-hydroxy-2-propyl-phenoxy)-acetic acid ethyl ester;
(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-2-propyl-phenoxy)-acetic acid; and
(3-Allyloxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester.

30. (Previously presented) A compound according to claim 27 selected from:
(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid methyl ester;
(4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid methyl ester;
(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
4-(2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl)-phenoxy)-acetic acid isopropyl ester;
(4-[2-[5-(Imino-methoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid isopropyl ester;
(4-[2-[5-(Imino-isobutoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid isopropyl ester;
(4-[2-[5-(Benzylloxycarbonylamino-imino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid isopropyl ester;
(4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid isopropyl ester;
(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic

acid isobutyl ester;

(4-{2-[5-(Imino-methoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-(Imino-isobutoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-(Benzylloxycarbonylamino-imino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-(Imino-methanesulfonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid isobutyl ester;

(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid benzyl ester;

(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid;

(4-{2-[5-(Imino-methoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid benzyl ester;

(4-{2-[5-(Imino-isobutoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid benzyl ester;

(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-ethoxy carbonyl methoxy-phenoxy)-acetic acid ethyl ester;

(2-Ethoxycarbonylmethoxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid ethyl ester;

(2-Ethoxycarbonylmethoxy-4-{2-[5-(imino-(3-methyl-butylamino)-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid ethyl ester;

(2-Ethoxycarbonylmethoxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-

isoindol-2-yl]-1-hydroxyimino-ethyl}-phenoxy)-acetic acid ethyl ester;
(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-isobutoxy carbonyl methoxy-phenoxy)-acetic acid isobutyl ester;
2-(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-NN-diethyl-acetamide;
4-(2-{4-[2-(5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl)-acetyl]-phenoxy}-acetoxy)-piperidine-1-carboxylic acid benzyl ester;
4-Benzylloxycarbonylamino-2-(4-{2-[5-carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-butyric acid ethyl ester;
4-Benzylloxycarbonylamino-2-(4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-butyric acid ethyl ester;
(4-{2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenylsulfanyl)-acetic acid methyl ester;
(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-chloro-phenoxy)-acetic acid ethyl ester;
(2-Chloro-4-{2-[5-(imino-isobutoxycarbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-phenoxy)-acetic acid ethyl ester;
(2-Chloro-4-(2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl)-phenoxy)-acetic acid ethyl ester;
(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-ethyl sulfanyl-phenoxy)-acetic acid ethyl ester;
(2-Ethylsulfanyl-4-(2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl)-phenoxy)-acetic acid ethyl ester;
(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-ethane sulfonyl-phenoxy)-acetic acid ethyl ester;
(2-Ethanesulfonyl-4-(2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-

2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(2,6-Bis-ethylsulfanyl-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(2-Acetylamino-4-[2-[5-N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(2-(Ethoxycarbonylmethyl-methanesulfonyl-amino)-4-[2-[5-(imino-isobutoxy carbonylamino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(2-(Ethoxycarbonylmethyl-methanesulfonyl-amino)-4-[2-[5-(N-hydroxy carbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-hydroxy-phenoxy)-acetic acid ethyl ester;
(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid benzyl ester;
(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-hydroxy-phenoxy)-acetic acid;
(4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-methoxy-phenoxy)-acetic acid ethyl ester;
(4-[2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-propoxy-phenoxy)-acetic acid ethyl ester;
(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-ethoxy carbonylmethoxy-phenoxy)-acetic acid ethyl ester;
(3-Ethoxycarbonylmethoxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-

isoindol-2-yl]-acetyl]-phenoxy)-acetic acid;
(2-Ethylsulfanyl-3-hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(2-Ethyl-5-hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(5-Hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-isopropyl-phenoxy)-acetic acid ethyl ester;
(2-*tert*-Butyl-5-hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(2-Chloro-5-hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(2-Chloro-3-hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(3-Hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-methyl-phenoxy)-acetic acid ethyl ester;
(3-Hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-methyl-phenoxy)-acetic acid benzyl ester;
(2-Ethyl-3-hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;
(3-Hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-propyl-phenoxy)-acetic acid ethyl ester;
(3-Hydroxy-4-{2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-2-propyl-phenoxy)-acetic acid benzyl ester;
(4-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-3-hydroxy-2-propyl-phenoxy)-acetic acid;

(4-Hydroxy-3-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-5-methoxy-phenoxy)-acetic acid ethyl ester;

(3,5-Dihydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2-Ethoxycarbonylmethoxy-3-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(2-Ethoxycarbonylmethoxy-5-hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(4-[2-[5-Acetimidoylamino-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-hydroxy-phenoxy)-acetic acid ethyl ester;

(3-Ethoxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(4-[2-(5-carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl)-acetyl]-3-ethoxy-phenoxy)-acetic acid ethyl ester;

(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-ethoxy-phenoxy)-acetic acid;

(3-Hydroxy-4-[2-[1-oxo-5-(5-oxo-2,5-dihydro-[1,2,4]oxadiazol-3-yl)-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;

(4-[2-[5-(Acetylamino-imino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-hydroxy-phenoxy)-acetic acid ethyl ester;

(3-Acetoxy-4-[2-[5-(5-methyl-[1,2,4]oxadiazol-3-yl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester;


(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-3-hydroxy-2-propyl-phenoxy)-acetic acid ethyl ester;

(3-Hydroxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-2-propyl-phenoxy)-acetic acid; and

(3-Allyloxy-4-[2-[5-(N-hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-phenoxy)-acetic acid ethyl ester.

31. (Previously presented) A compound according to claim 28 selected from:
(4-[2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl]-piperazine-1-yl)-acetic acid ethyl ester;
(1-{2S-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-3-(4-hydroxy-phenyl)-propionyl}-piperidin-4-yloxy)-acetic acid ethyl ester;
(1-{2-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-piperidin-4-yloxy)-acetic acid ethyl ester;
(1-{3-[5-(N-Hydroxycarbamimidoyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionyl}-piperidin-4-yloxy)-acetic acid ethyl ester;
(1-{2-[5-(5-Methyl-isoxazol-3-yl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-piperidin-4-yloxy)-acetic acid ethyl ester;
(1-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-piperidin-4-yloxy)-acetic acid ethyl ester;
(1-{2-[5-(tert-Butoxycarbonyl-amino-imino-methyl)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-piperidin-4-yloxy)-acetic acid ethyl ester; and
(1-{2-[5-Carbamimidoyl-1-oxo-1,3-dihydro-isoindol-2-yl]-acetyl}-piperidin-4-yloxy)-acetic acid.

32. (Withdrawn) A process for the preparation of a compound of general formula (I):





wherein

ring A is phenyl;


R^A is selected from: -(CH₂)_pCN, -C(=NR¹)-SMe and -C(=NR¹)-OMe , or

R^A is selected from one of the following groups of formula (2), formula (3) and formula (4):



(2)

(3)



(4)

wherein p is 0, 1 or 2;

s is 1 or 2, and when s is 2 the groups R^A are independent of each other and can be the same or different;

R¹ and R² are independently selected from: H, hydroxy, alkyl, partially or fully fluorinated alkyl, alkoxy, alkenyl, alkynyl, carboxy, -C(=O)OR⁵, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl and heterocycle; or R¹ and R², together with the nitrogen atom to which they are attached, form a saturated, partially saturated or aromatic heterocycle, optionally containing at least one additional hetero atom selected from: N, O and S;

R³ and R⁴ are independently selected from: H, alkyl, partially or fully fluorinated alkyl, alkenyl, alkynyl, -C(=O)OR⁵, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl,

heterocycle, -OR⁵, -SR⁵, -NR⁵R⁶, -S(=O)₂NR⁵R⁶, -S(=O)₂R⁵, -C(=O)R⁵, -C(=O)NR⁵R⁶, -C(=O)OR⁵, -C(=O)SR⁵, -OC(=O)R⁵, -OC(=O)OR⁵, -OC(=O)NR⁵R⁶, -OS(=O)₂R⁵, -S(C=O)NR⁵ and -OS(=O)₂NR⁵R⁶, or R³ and R¹ or R⁴, together with the respective nitrogen atoms to which they are attached, form an unsubstituted or substituted 5-, 6- or 7-membered partially saturated or aromatic heterocycle, optionally having one or more additional heteroatoms selected from: N, O and S, wherein the substituents are selected from: hydroxy, halogen, alkyl, alkoxy, alkenyl, alkynyl, oxo, carboxy and -C(=O)OR⁵;

R⁵ and R⁶ are independently selected from: H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl and heterocycle, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkylalkyl group optionally contains at least one hetero atom selected from: N, S and O anywhere in the chain, including the terminal position;

R⁷ and R⁹ have the same meaning as R³ and R⁴, defined above;

R⁸ is selected from: H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl and heterocycle, wherein said heterocycle is saturated, partially saturated or aromatic and contains at least one hetero atom selected from: N, O and S, with its point of attachment either through C or N, and wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkylalkyl groups optionally contains at least one hetero atom selected from: N, O and S, anywhere in the chain, including the terminal position;

R^B is selected from: H, halogen, -CN, -NO₂, alkyl, partially or fully fluorinated alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycle, -NR¹⁰R¹¹, -OR¹⁰, -SR¹⁰, S(O)R¹⁰, S(O)₂R¹⁰, -NHC(=O)R¹⁰, -NHOR¹⁰, -OC(=O)R¹⁰, -SC(=O)R¹⁰, -NHC(=O)OR¹⁰, -OC(=O)OR¹⁰, -C(=O)NR¹⁰R¹¹, -C(=O)R¹⁰, and -C(=O)OR¹⁰;

Applicant: Bansilal et al.
Application No.: 10/574,982

R¹⁰ and R¹¹ have the same meaning as R⁵ and R⁶, defined above

Y¹ and Y², together, are selected from: =O and =S;

R¹² and R¹³ are selected from: H, OR⁵, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl and aryl;

Z is N;

W is CH₂;

R^C is selected from: H, alkyl, aryl, heterocycle, =O, =NR¹⁴, =S, CN, NR¹⁴R¹⁵, OR¹⁴, SR¹⁴, S(=O)₂R¹⁶ and COR¹⁶;

R¹⁴ and R¹⁵ have the same meaning as R⁵ and R⁶, defined above;

R¹⁶ is selected from: H, OR¹⁴, N(R¹⁴)₂, NR¹⁴R¹⁵, SR¹⁴ and R⁵, wherein R⁵, R¹⁴ and R¹⁵ are as defined above;

n is 0, 1, 2 or 3;

R^D and R^E are independently selected from: H and an unsubstituted or substituted group selected from: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl and heterocycle, wherein the substituents are selected from: hydroxy, halogen, alkyl, alkenyl, alkynyl, oxo, carboxy, -C(=O)OR⁵, -OR¹⁷, -SR¹⁷, -NR¹⁷R¹⁸, -NHC(=O)R¹⁷, -NHC(=O)OR¹⁷, -OC(=O)R¹⁷, -SC(=O)R¹⁷, -OS(=O)₂R¹⁷ and -NHS(=O)₂R¹⁷;

R¹⁷ and R¹⁸ have the same meaning as R⁵ and R⁶, defined above;

R^F is selected from: O, S and N(OR¹⁹);

R¹⁹ and R²⁰ have the same meaning as R⁵ and R⁶, defined above;

R^G is selected from: aryl, heteroaryl, and partially or fully saturated heterocycle, where said aryl, heteroaryl and heterocycle are substituted by one or more groups of the formula (5):



and optionally, further substituted by one or more groups selected from: -R⁵,

halogen, -CN, -SCN, -CNO, -OR²¹, -OC(=O)R²¹, -OS(=O)₂R²¹, -OS(=O)₂NR²¹R²², -OC(=O)OR²¹, -OC(=O)SR²¹, -OC(=O)NR²¹R²², -SR²¹, -S(=O)R²¹, -SC(=O)H, -SC(=O)OR²¹, -NO₂, -NR²¹(OR²²), -NR²¹R²², -NR²¹C(=O)R²², -N(R²¹)C(=O)OR²², -N[S(=O)₂R²¹]R²³, C(=O)OR²¹, -S(=O)₂R²¹ and -S(=O)₂OR²¹;

R²¹ and R²² have the same meaning as R¹ and R², defined above:

T is selected from: -CH₂, O, S and NH;


q is 0, 1, 2 or 3;

R²³ and R²⁴ are independently selected from: H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycle and C(=O)R²⁵, wherein said alkyl and alkenyl optionally contain at least one hetero atom selected from: O, S and N, in any position of the alkyl or alkenyl chain, and said alkyl and alkenyl are unsubstituted or substituted with at least one group selected from: -OR¹, -OC(=O)R¹, -OS(=O)₂R¹, -S(=O)₂NR¹R², -OC(=O)OR¹, -OC(=O)SR¹, -OC(=O)NR¹R², -SR¹, -S(=O)R¹, -SC(=O)H, -SC(=O)OR¹, -NR¹(OR²), -NR¹R², -NR¹C(=O)R², -N(R¹)C(=O)OR², -NR¹S(=O)₂R², C(=O)OR¹, -S(=O)₂R¹ and -S(=O)₂OR¹;

R²⁵ is selected from: OR⁵, SR⁵, -OCR³R⁴ and -NR⁵R⁶, wherein R³, R⁴, R⁵ and R⁶ are as defined above and wherein optionally, R³ and R⁴, together with the carbon to which they are attached, form an unsubstituted or substituted 5-, 6- or 7-membered saturated, partially saturated or aromatic heterocycle having one or more heteroatoms selected from: N, O and S, wherein the substituents are selected from: hydroxy, halogen, alkyl, alkoxy, alkenyl, alkynyl, oxo, carboxy and -C(=O)OR⁵; and the group NR⁵R⁶ is, optionally, a heterocycle containing at least one additional heteroatom selected from: O, S, and N;


which process comprises

- (a) reacting compound of formula (II):



wherein


L is a leaving group; and all other symbols are as defined above; with a compound of the formula (III):



wherein all symbols are as defined above;

in the presence of an organic or inorganic base in an organic solvent or a mixture of at least two different organic solvents, at a temperature ranging from -40°C to 150°C, for 0.5 to 16 h, to effect in situ cyclization to form a compound of the general formula (I) above, and, optionally, converting the compound into a physiologically tolerable salt; or


b) reacting a compound of the formula (IV)



wherein


L₂ is a leaving group; and all other symbols are as defined above; with a compound of the formula (V):

Applicant: Bansilal et al.
Application No.: 10/574,982




where R^G is selected from: piperidinyl, piperazinyl and phenyl, wherein said piperidinyl, piperazinyl and phenyl, are optionally substituted with 1, 2, 3 or 4 hydroxyl groups, and all other symbols are as defined above, in the presence of an organic or inorganic base in an organic solvent or water at a temperature ranging from 0°C to 150°C, for 0.5 to 12 h, to form a compound of the general formula (I), and, optionally, converting one or more of the hydroxyl groups into a group selected from the substituents for R^G as defined in general formula (I) and, optionally, converting the compound into a physiologically tolerable salt; alternatively, activating a compound of the formula (IV) above, wherein L_2 is -OH, by treatment with a mixed anhydride to form a peptide coupling with a compound of the formula (V), wherein R^G is piperidinyl or piperazinyl, and thereby provide a compound of the general formula (I), wherein R^G is piperidinyl or piperazinyl substituted with at least a group of the formula (5); and, optionally, converting the resultant compound into a physiologically tolerable salt; or

c) alkylating a compound of the formula (VIII):



wherein B is halogen, acetate or formate, and all other symbols are as defined above;

with a compound of the formula:



wherein

R^{G} is phenyl, having at least one substituent which is $\text{OCH}_2\text{Phenyl}$, and optionally at least one further substituent selected from: $-\text{R}^5$, halogen, $-\text{CN}$, $-\text{SCN}$, $-\text{CNO}$, $-\text{OR}^{21}$, $-\text{OC}(=\text{O})\text{R}^{21}$, $-\text{OS}(=\text{O})_2\text{R}^{21}$, $-\text{OS}(=\text{O})_2\text{NR}^{21}\text{R}^{22}$, $-\text{OC}(=\text{O})\text{OR}^{21}$, $-\text{OC}(=\text{O})\text{SR}^{21}$, $-\text{OC}(=\text{O})\text{NR}^{21}\text{R}^{22}$, $-\text{SR}^{21}$, $-\text{S}(=\text{O})\text{R}^{21}$, $-\text{SC}(=\text{O})\text{H}$, $-\text{SC}(=\text{O})\text{OR}^{21}$, $-\text{NO}_2$, $-\text{NR}^{21}\text{OH}$, $-\text{NR}^{21}(\text{OR}^{22})$, $-\text{NR}^{21}\text{R}^{22}$, $-\text{NR}^{21}\text{C}(=\text{O})\text{R}^{22}$, $-\text{N}(\text{R}^{21})\text{C}(=\text{O})\text{OR}^{22}$, $-\text{N}[\text{S}(=\text{O})_2\text{R}^{21}] \text{R}^{23}$, $\text{C}(=\text{O})\text{OR}^{21}$, $-\text{S}(=\text{O})_2\text{R}^{21}$ and $-\text{S}(=\text{O})_2\text{OR}^{21}$; and

L_3 is a leaving group; and all other symbols are as defined above;

in the presence of an organic or inorganic base in an organic solvent or a mixture of at least two different organic solvents, at a temperature ranging from -40°C to 150°C , for 0.5 to 16 h, to effect in situ cyclization to form the compound of general formula (I), wherein R^{G} is phenyl having atleast one substitutent which is $-\text{OCH}_2\text{Phenyl}$, R^{A} is $-\text{COOEt}$ and s is 2; converting the $-\text{OCH}_2\text{Phenyl}$ into hydroxyl and subsequently coupling the hydroxyl with the group $\text{L}_4-(\text{CH}_2)_q-\text{CR}^{23}\text{R}^{24}\text{COR}^{25}$, where L_4 is a leaving group;


optionally converting one or both of the $-\text{COOEt}$ groups into the cyano group $-(\text{CH}_2)_p\text{CN}$, wherein p is as defined; optionally, subsequently converting at least one of the cyano groups into a group of the formula (3), as defined; and, optionally, converting the resultant compound into a physiologically tolerable salt.

33. (Previously presented) A pharmaceutical composition, comprising a compound of formula (I) according to claim 25, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
34. (Previously presented) A pharmaceutical composition for inhibiting the binding of fibrinogen to blood platelets, comprising a compound of formula (I) according to claim 25, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
35. (Previously presented) A pharmaceutical composition for inhibiting the binding of fibrinogen to blood platelets, comprising a compound of formula (I) according to claim 25, or a pharmaceutically acceptable salt thereof, in combination with an antithrombotic agent and a pharmaceutically acceptable carrier.
36. (Withdrawn) The use of a compound according to claim 25, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the inhibition of the binding of fibrinogen to blood platelets.
37. (Withdrawn) The use of a compound according to claim 25, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of cardiovascular and cerebrovascular thromboembolic diseases.
38. (Withdrawn) The use according to claim 37 wherein the cardiovascular and cerebrovascular thromboembolic diseases include: arterial thromboembolism,


cerebral thromboembolism, cerebral arterial thrombosis, coronary thrombosis, deep vein thrombosis, diabetes-related thromboembolic disorders, sudden ischemic emergencies, myocardial infarction, pulmonary thromboembolisms, stroke, thrombophlebitis, transient ischemic attack, unstable angina and venous thrombosis or kidney thromboembolism.

39. (Withdrawn) The use of a compound according to claim 25, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the inhibition of blood platelet aggregation.
40. (Withdrawn) The use according to claim 39, wherein blood platelet aggregation includes platelet thrombosis, thromboembolism and reocclusion during and after thrombolytic therapy and platelet thrombosis, thromboembolism and reocclusion after angioplasty or coronary artery bypass surgery, and blood clots after orthopedic surgery.
41. (Withdrawn) The use of a compound according to claim 25, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention and treatment of diseases involving a cell adhesion process.
42. (Withdrawn) The use according to claim 41, wherein diseases involving a cell adhesion process include: adult respiratory distress syndrome, allergies, asthma, rupture of atherosclerotic plaques, autoimmune diseases, inflammation, bone degradation, contact dermatitis, diabetic retinopathy, eczema, graft versus host disease, inflammatory bowel disease, metastasis, organ transplantation rejection, osteoarthritis, osteoporosis, psoriasis, rheumatoid arthritis, septic shock and tumors.
43. (Withdrawn) A process according to claim 32, wherein

the compound of the formula (VII),




wherein R^{G} is the substituted phenyl group below:



wherein R is a group of the formula (5); R^{F} is O; R^{D} , R^{E} , n and L_3 are as defined;

is prepared by


reacting the O-allylic compound H-60




wherein R^{a} , R^{b} and R^{c} are independently selected from: alkyl and alkylaryl, and R has the meaning defined above, with the compound $\text{L}_3(\text{CH}_2)_n\text{CR}^{\text{D}}\text{R}^{\text{E}}\text{COCl}$, wherein L_3 is a leaving group, R^{D} , R^{E} and n are as defined, in the presence of a catalyst and an organic solvent or mixture of at least two organic solvents at a temperature ranging from room temperature to 120°C, for a period of 2 to 12 h and, optionally, isolating the compound of formula (VII) from the reaction mixture.

44. (Withdrawn) A process according to claim 32, wherein a compound of the

formula (III)y:




where R^{G} is the group



wherein R^{K} , R^{L} , R^{V} and R^{U} , are independently selected from: H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, halogen, -CN, -SCN, -CNO, -OR²¹, -OC(=O)R²¹, -OS(=O)₂R²¹, -OS(=O)₂NR²¹R²², -OC(=O)OR²¹, -OC(=O)SR²¹, -OC(=O)NR²¹R²², -SR²¹, -S(=O)R²¹, -SC(=O)H, -SC(=O)OR²¹, -NO₂, -NR²¹(OR²²), -NR²¹R²², -NR²¹C(=O)R²², -N(R²¹)C(=O)OR²², -N[S(=O)₂R²¹]R²³, C(=O)OR²¹, -S(=O)₂R²¹, -S(=O)₂OR²¹ and a group of formula (5);

R' is a protected amino group; R^{F} is O; and R^{D} , R^{E} and n are as defined; with the proviso that at least one of the groups R^{K} , R^{L} , R^{V} and R^{U} is a group of the formula (5) and at least one of the remaining R^{K} , R^{L} , R^{V} and R^{U} is OH; is prepared by reacting a mono- or polyhydroxy phenol of the formula (IX):



wherein R^{21} is selected from H, alkyl or aralkyl; and R^{K} , R^{L} , R^{V} and R^{U} have the meaning defined above; with a compound of formula (X):



Applicant: Bansi Lal et al.
Application No.: 10/574,982

wherein

R^D, R^E and n are as defined above,

R/ is a protected amino group;

in the presence of an inorganic acid and a catalyst at a temperature in the range of 0°C to 60°C, for a period of 2 to 12 h, in an organic solvent or a mixture of at least two organic solvents, and optionally, isolating the compound of formula (III) from the reaction mixture.